Cost Effectiveness Of Sunitinib Vs IFN-Alfa Or Bevacizumab + IFN-Alfa As First-Line Treatment In MRCC In Central America And The Caribbean.

Trial Profile

Cost Effectiveness Of Sunitinib Vs IFN-Alfa Or Bevacizumab + IFN-Alfa As First-Line Treatment In MRCC In Central America And The Caribbean.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 21 Sep 2011

At a glance

  • Drugs Bevacizumab; Interferon alpha; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 21 Sep 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 22 Aug 2011 Actual end date (February 2011) added as reported by ClinicalTrials.gov.
    • 22 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top